Centre Léon Bérard

Site:	Centre Léon Bérard
Address:	28 rue Laennec
City:	Lyon
State:	Rhone
Zip:	69373
Country:	France

25 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
2	Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)	Completed	Active	Regorafenib (SDH)	NCT02638766
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
2	Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)	Active, not recruiting	Closed	Pembrolizumab + Cyclophosphamide	NCT02406781
2	Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)	Completed	Closed	Pazopanib (Votrient)	NCT01323400
2	Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)	Ongoing, but not recruiting	Closed	Palbociclib	NCT01907607
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
1	A Study of NB003 in Patients With Advanced Malignancies	Recruiting	Active	NB003	NCT04936178
3	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Terminated	Active	Masitinib, (AB1010)	NCT00812240
1	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers	Completed	Closed	Masitinib, (AB1010)
2	Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)	Recruiting	Active	Lenvatinib	NCT04193553
2	A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)	Active, not recruiting	Active	Imatinib + Regorafenib	NCT02365441
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
1	A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BKM120	NCT01468688
2	A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)	Recruiting	Active	Imatinib + Atezolizumab	NCT05152472
3	Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance	Completed	Closed	Imatinib	NCT00367861
3	Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate	Terminated	Closed	Imatinib	NCT00956072
3	Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)	Completed	Closed	Imatinib	NCT02260505

Centre Léon Bérard

25 trials at this site

Page 1 of 2 | Next | Last